Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laboratorios Farmaceuticos Rovi's revenue for the
three
months ended in Jun. 2026 was €191.7 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €773.1 Mil.
Laboratorios Farmaceuticos Rovi's Revenue per Share for the
three
months ended in Jun. 2026 was €3.75.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €15.11.
Warning Sign:
Laboratorios Farmaceuticos Rovi SA revenue per share has been in decline over the past 3 years.
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest 3-Year average Revenue per Share Growth Rate was 30.30% per year. The lowest was -1.70% per year. And the median was 10.70% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Laboratorios Farmaceuticos Rovi Revenue Related Terms
Laboratorios Farmaceuticos Rovi Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Revenue distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €773.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (FRA:41L) has a Revenue of €773.1 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's Revenue too high?
Laboratorios Farmaceuticos Rovi's current Revenue is €773.1 Mil. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Revenue compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Revenue of €773.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Revenue is €773.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (FRA:41L) is currently considered Fairly Valued. The stock's GF Value™ is €54.02, compared to a current price of €58.55 — trading 8.4% above its estimated fair value. The current Revenue is €773.1 Mil. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (FRA:41L), the current Revenue is €773.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (FRA:41L) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of €58.55 is trading 8.4% above its estimated GF Value™ of €54.02.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Fairly Valued.
Key valuation signals for FRA:41L:
Revenue: €773.1 Mil
GF Value™: €54.02 vs. price of €58.55 (8.4% above fair value)
No single metric tells the full story. See the FRA:41L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
89GF Score
Get the complete analysis for FRA:41L
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:41L has been successfully added to your 
